Apertor Pharmaceuticals
June 25, 2026
Theater 1
Type: Company Presentation
Focus Area:
Oncology
Apertor Pharmaceuticals is creating novel molecular glues for therapeutic applications in oncology. At Apertor we have developed a new class of therapeutics to address one of the toughest challenges in drug discovery — selective disruption of disease-causing protein-protein interactions (PPIs). Apertor’s Interceptors are designed to selectively disrupt protein complexes via proximity induction by recruiting an abundantly expressed protein naturally found in cancerous cells patient’s own proteins to safely and effectively block PPIs .
Apertor has identified its first development candidate targeting the mTORC1/4E-BP1 complex for the treatment of lung squamous cell carcinoma, and has built a robust pipeline of additional programs addressing high-value oncology targets.
Apertor was founded in late 2020 and anticipates filing an IND in 2027 and is targeting a clinical study in non-small cell lung cancer (NSCLC).
Company HQ City:
South San Francisco
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2020
Lead Product in Development:
AP-457
CEO
Edmund Graziani
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
3
When you expect your next catalyst update?
1H2027
What is your next catalyst (value inflection) update?
IND
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}